A previous clinical trial found that tamoxifen, taken for five years, reduced the risk of developing invasive breast cancer by about 50% in post-menopausal women who were at increased risk of getting the disease.
Another trial found that five years of raloxifene reduces breast cancer risk in such women by about 38%.
Under the new plans, high risk post-menopausal women could be offered the drugs for a period of five years unless they have a history of thromboembolic disease or endometrial cancer.
More top news
Largely dry night, but showers set to spread in from the west during tomorrow
Two people have died after being involved in separate lightning strikes in Wales' Brecon Beacons today.
France's Champagne and Burgundy wine regions have been granted Unesco world heritage status, as the remit for the title broadens.